NASDAQ:SKYE Skye Bioscience Q2 2026 Earnings Report $0.50 -0.04 (-7.30%) Closing price 03:59 PM EasternExtended Trading$0.63 +0.13 (+25.22%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Skye Bioscience EPS ResultsActual EPS-$0.27Consensus EPS -$0.29Beat/MissBeat by +$0.02One Year Ago EPSN/ASkye Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASkye Bioscience Announcement DetailsQuarterQ2 2026Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time4:00PM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Skye Bioscience Earnings HeadlinesSkye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks TranscriptAugust 14 at 6:00 PM | seekingalpha.comSkye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in FinancingsAugust 14 at 9:33 AM | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 14 at 1:00 AM | Stansberry Research (Ad)Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 7, 2026 | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Shares Up 2.8% - What's Next?August 4, 2026 | americanbankingnews.comCadrenal Therapeutics Names Sharp Interim CFOJune 29, 2026 | marketwatch.comSee More Skye Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email. Email Address About Skye BioscienceSkye Bioscience (NASDAQ:SKYE) is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure. Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies. By targeting CB1 receptors in ocular tissues, the company aims to deliver localized efficacy while minimizing systemic exposure. Preclinical studies have demonstrated promising pharmacokinetic and pharmacodynamic profiles, supporting the potential for twice-daily topical administration and rapid onset of action. Founded in 2018, Skye Bioscience has assembled a multidisciplinary leadership team with expertise in pharmacology, medicinal chemistry and ophthalmology. The company collaborates with contract research organizations and academic partners to advance its clinical programs through regulatory milestones and into human trials. As a Nasdaq-listed entity under the symbol SKYE, Skye Bioscience is positioning itself at the forefront of cannabinoid-derived therapeutics for eye health.View Skye Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
